Broussonetine A exhibits significant potential in neuropharmacological applications due to its acetylcholinesterase (AChE) inhibitory activity. This property makes it a candidate for the development of treatments for neurodegenerative disorders such as Alzheimer’s disease, where enhancing cholinergic transmission is a key therapeutic strategy. Its natural origin and specific mechanism of action support further investigation into its use as a lead compound for cognitive enhancers. Additionally, preliminary studies suggest anti-inflammatory and neuroprotective effects, broadening its possible applications in brain health and neurological therapeutics. Research is ongoing to evaluate its bioavailability, safety, and efficacy in preclinical models.